BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim TS, Moon WK, Lee DS, Chung JK, Lee MC, Youn YK, Oh SK, Choe KJ, Noh DY. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg. 2001;25:829-834. [PMID: 11572019 DOI: 10.1007/s002680020095] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Landheer MLEA, Steffens MG, Klinkenbijl JHG, Westenberg AH, Oyen WJG. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. British Journal of Surgery 2005;92:1363-7. [DOI: 10.1002/bjs.5046] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
2 Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332. [PMID: 15044750 DOI: 10.1148/radiol.2312021185] [Cited by in Crossref: 541] [Cited by in F6Publishing: 445] [Article Influence: 31.8] [Reference Citation Analysis]
3 Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, Endo K. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci. 2006;97:1291-1297. [PMID: 17052261 DOI: 10.1111/j.1349-7006.2006.00341.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
4 Eubank WB. Diagnosis of Recurrent and Metastatic Disease Using F-18 Fluorodeoxyglucose-Positron Emission Tomography. PET Clinics 2006;1:15-24. [DOI: 10.1016/j.cpet.2005.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 van Oost F, van der Hoeven J, Hoekstra O, Voogd A, Coebergh J, van de Poll-franse L. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. European Journal of Cancer 2004;40:1545-53. [DOI: 10.1016/j.ejca.2004.03.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
6 Sekiyama S, Umezawa M, Iizumi Y, Ube T, Okazaki T, Kamimura M, Soga K. Delayed Increase in Near-Infrared Fluorescence in Cultured Murine Cancer Cells Labeled with Oxygen-Doped Single-Walled Carbon Nanotubes. Langmuir 2019;35:831-7. [DOI: 10.1021/acs.langmuir.8b03789] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
7 Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol. 2010;136:1007-1022. [PMID: 20091186 DOI: 10.1007/s00432-009-0746-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
8 Weir L, Worsley D, Bernstein V. The Value of FDG Positron Emission Tomography in the Management of Patients with Breast Cancer. Breast Journal 2005;11:204-9. [DOI: 10.1111/j.1075-122x.2005.21625.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
9 Spanu A, Farris A, Schillaci O, Chessa F, Solinas ME, Falchi A, Madeddu G, Nuvoli S, Madeddu G. The usefulness of 99mTc tetrofosmin scintigraphy in patients with breast cancer recurrences: . Nuclear Medicine Communications 2003;24:145-54. [DOI: 10.1097/00006231-200302000-00007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Xiao Y, Wang L, Jiang X, She W, He L, Hu G. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis. Nuclear Medicine Communications 2016;37:1180-8. [DOI: 10.1097/mnm.0000000000000573] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Constantinidou A, Martin A, Sharma B, Johnston S. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Annals of Oncology 2011;22:307-14. [DOI: 10.1093/annonc/mdq343] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
12 Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27 Suppl 1:S215-S229. [PMID: 18180228 DOI: 10.1148/rg.27si075517] [Cited by in Crossref: 174] [Cited by in F6Publishing: 122] [Article Influence: 13.4] [Reference Citation Analysis]
13 Roop MJ, Singh B, Singh H, Watts A, Kohli PS, Mittal BR, Singh G. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer. Clin Nucl Med 2017;42:335-40. [PMID: 28263210 DOI: 10.1097/RLU.0000000000001615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Bhoriwal S, Deo SVS, Kumar R, Thulkar S, Gogia A, Sharma DN, Mathur S. A Prospective Study Comparing the Role of 18 FDG PET-CT with Contrast-Enhanced Computed Tomography and Tc99m Bone Scan for Staging Locally Advanced Breast Cancer. Indian J Surg Oncol 2021;12:266-71. [PMID: 34295069 DOI: 10.1007/s13193-021-01299-4] [Reference Citation Analysis]
15 Ahmed Shamim S, Torigian DA, Kumar R. PET, PET/CT, and PET/MR Imaging Assessment of Breast Cancer. PET Clin 2008;3:381-93. [PMID: 27156667 DOI: 10.1016/j.cpet.2009.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Siggelkow W, Rath W, Buell U, Zimny M. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S118-24. [PMID: 15146295 DOI: 10.1007/s00259-004-1534-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
17 Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg. 2002;184:383-393. [PMID: 12433599 DOI: 10.1016/s0002-9610(02)01012-7] [Cited by in Crossref: 449] [Cited by in F6Publishing: 116] [Article Influence: 23.6] [Reference Citation Analysis]
18 Eubank WB, Mankoff DA. Current and future uses of positron emission tomography in breast cancer imaging. Seminars in Nuclear Medicine 2004;34:224-40. [DOI: 10.1053/j.semnuclmed.2004.03.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
19 Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003;129:147-53. [PMID: 12712329 DOI: 10.1007/s00432-003-0424-z] [Cited by in Crossref: 66] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
20 Planchard D, Soria J, Michiels S, Grunenwald D, Validire P, Caliandro R, Girard P, Le Chevalier T. Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer 2004;100:28-35. [DOI: 10.1002/cncr.11881] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
21 Hong R, Lim SC. 18F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma. World J Gastroenterol 2012; 18(2): 168-174 [PMID: 22253523 DOI: 10.3748/wjg.v18.i2.168] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
22 Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci. 2008;99:260-266. [PMID: 18271924 DOI: 10.1111/j.1349-7006.2007.00683.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
23 Klaeser B, Wiederkehr O, Koeberle D, Mueller A, Bubeck B, Thuerlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Annals of Oncology 2007;18:1329-34. [DOI: 10.1093/annonc/mdm139] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
24 Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995-4000. [PMID: 14581422 DOI: 10.1200/jco.2003.04.073] [Cited by in Crossref: 147] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
25 Jung NY, Yoo IR, Kang BJ, Kim SH, Chae BJ, Seo YY. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients. Breast Cancer 2016;23:141-8. [PMID: 24872087 DOI: 10.1007/s12282-014-0542-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
26 Zimny M, Siggelkow W. Positron emission tomography scanning in gynecologic and breast cancers. Curr Opin Obstet Gynecol 2003;15:69-75. [PMID: 12544505 DOI: 10.1097/00001703-200302000-00011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
27 Schuster DM, Halkar RK. Molecular imaging in breast cancer. Radiologic Clinics of North America 2004;42:885-908. [DOI: 10.1016/j.rcl.2004.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
28 Escalona S, Blasco JA, Reza MM, Andradas E, Gómez N. A systematic review of FDG-PET in breast cancer. Med Oncol 2010;27:114-29. [DOI: 10.1007/s12032-009-9182-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
29 Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Seminars in Nuclear Medicine 2005;35:84-99. [DOI: 10.1053/j.semnuclmed.2004.11.001] [Cited by in Crossref: 134] [Cited by in F6Publishing: 89] [Article Influence: 8.4] [Reference Citation Analysis]
30 Bénard F, Turcotte E. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res 2005;7:153-62. [PMID: 15987467 DOI: 10.1186/bcr1201] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
31 Lebron L, Greenspan D, Pandit-Taskar N. PET Imaging of Breast Cancer: Role in Patient Management. PET Clin 2015;10:159-95. [PMID: 25829085 DOI: 10.1016/j.cpet.2014.12.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
32 Kumar R, Alavi A. Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 2004;42:1113-22, ix. [PMID: 15488561 DOI: 10.1016/j.rcl.2004.08.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
33 Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008;26:712-20. [PMID: 18258978 DOI: 10.1200/JCO.2007.13.8412] [Cited by in Crossref: 80] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
34 Wolfort RM, Li BD, Johnson LW, Turnage RH, Lilien D, Ampil F, Burton G, Chu QD. The role of whole-body fluorine-18-FDG positron emission tomography in the detection of recurrence in symptomatic patients with stages II and III breast cancer. World J Surg 2006;30:1422-7. [PMID: 16715451 DOI: 10.1007/s00268-005-0207-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
35 Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105-12. [DOI: 10.1007/s10549-004-3291-7] [Cited by in Crossref: 126] [Cited by in F6Publishing: 86] [Article Influence: 7.9] [Reference Citation Analysis]
36 Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun 2012;33:591-6. [PMID: 22334135 DOI: 10.1097/MNM.0b013e3283516716] [Cited by in Crossref: 32] [Cited by in F6Publishing: 5] [Article Influence: 3.6] [Reference Citation Analysis]
37 Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C, Bozza F, Saladini G. Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT?: results from small population with previous breast cancer. Ann Nucl Med 2011;25:469-77. [PMID: 21476056 DOI: 10.1007/s12149-011-0488-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
38 Eubank WB. Diagnosis of Recurrent and Metastatic Disease Using F-18 Fluorodeoxyglucose-Positron Emission Tomography in Breast Cancer. Radiologic Clinics of North America 2007;45:659-67. [DOI: 10.1016/j.rcl.2007.05.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
39 Eubank WB, Lee JH, Mankoff DA. Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging. PET Clin 2009;4:299-312. [PMID: 20161481 DOI: 10.1016/j.cpet.2009.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]